Sei Investments Co. Sells 6,875 Shares of Celcuity, Inc. $CELC

Sei Investments Co. lowered its holdings in shares of Celcuity, Inc. (NASDAQ:CELC) by 32.5% in the 1st quarter, HoldingsChannel.com reports. The firm owned 14,306 shares of the company’s stock after selling 6,875 shares during the period. Sei Investments Co.’s holdings in Celcuity were worth $1,633,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC purchased a new position in Celcuity in the 4th quarter worth approximately $310,302,000. NEA Management Company LLC boosted its stake in Celcuity by 64.9% in the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after purchasing an additional 1,391,300 shares during the period. State Street Corp grew its holdings in Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after buying an additional 914,887 shares in the last quarter. UBS Group AG grew its holdings in Celcuity by 910.1% during the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after buying an additional 769,891 shares in the last quarter. Finally, Deerfield Management Company L.P. bought a new stake in shares of Celcuity during the third quarter valued at approximately $36,236,000. Institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Craig Hallum reissued a “buy” rating and issued a $178.00 target price on shares of Celcuity in a report on Wednesday, July 15th. Macquarie Infrastructure set a $160.00 price target on shares of Celcuity in a report on Thursday, May 28th. Guggenheim reiterated a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Wells Fargo & Company dropped their price objective on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Finally, Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $155.18.

Celcuity Stock Performance

Celcuity stock opened at $90.79 on Tuesday. The company’s 50-day moving average price is $93.93 and its 200-day moving average price is $108.99. Celcuity, Inc. has a twelve month low of $44.42 and a twelve month high of $151.02. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. The company has a market cap of $4.43 billion, a PE ratio of -23.28 and a beta of 0.21.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. On average, equities research analysts forecast that Celcuity, Inc. will post -3.76 EPS for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.